Ardelyx (ARDX) says FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments for Tenapanor at this time
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| Oppenheimer Rising Dividends Fund, Inc. Class A (NASDAQ: ARDX) | Delayed: 3.15 -0.06 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.21 | 52 Week High | $20.98 | |||
| Open | $3.23 | 52 Week Low | $6.36 | |||
| Day High | $3.23 | P/E | N/A | |||
| Day Low | $3.12 | EPS | $0.00 | |||
| Volume | 987,041 | |||||
